SLC22A31

Across TCGA pan-cancer cohorts, SLC22A31 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated SLC22A31 data layer compared with 3 for mutation status.

The strongest signal is observed in uveal melanoma (UVM), where higher SLC22A31 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC22A31 expression acts as an unfavorable survival marker, although some lineages such as MESO and SKCM show a favorable association.

UVM, KIRC, and LUSC are the cancer types where SLC22A31 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Median	All	0.384	0.768	<.001	103	view →
KIRC	OS	Tertile	All	0.514	0.685	<.001	95	view →
LUSC	DFS	Median	All	0.568	0.718	<.001	77	view →
KIRP	DFS	Tertile	All	0.758	1.000	.001	46	view →
MESO	OS	Tertile	III,IV	0.676	0.393	.010	41	view →
COAD	DFS	Median	II,III,IV	0.392	0.557	.004	40	view →
SKCM	DFS	Median	II,III,IV	0.751	0.628	.002	32	view →
UCEC	DFS	Quartile	II,III,IV	0.748	0.895	.006	26	view →
LUAD	OS	Tertile	All	0.849	0.746	.005	24	view →
LGG	OS	Median	All	0.864	0.754	<.001	20	view →
ESCA	DFS	Median	IV	0.213	0.626	.026	18	view →
BRCA	DFS	Tertile	All	0.684	0.391	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

SLC22A31–UVM (DFS)

Open the UVM breakdown →